GB201810667D0 - New compounds and uses - Google Patents

New compounds and uses

Info

Publication number
GB201810667D0
GB201810667D0 GBGB1810667.4A GB201810667A GB201810667D0 GB 201810667 D0 GB201810667 D0 GB 201810667D0 GB 201810667 A GB201810667 A GB 201810667A GB 201810667 D0 GB201810667 D0 GB 201810667D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1810667.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzecure Pharma AB
Original Assignee
Stiftelsen Alzecure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiftelsen Alzecure filed Critical Stiftelsen Alzecure
Priority to GBGB1810667.4A priority Critical patent/GB201810667D0/en
Publication of GB201810667D0 publication Critical patent/GB201810667D0/en
Priority to EP19710473.0A priority patent/EP3759088B8/en
Priority to CN201980014798.6A priority patent/CN111819172B/en
Priority to DK19710473.0T priority patent/DK3759088T3/en
Priority to FIEP19710473.0T priority patent/FI3759088T3/en
Priority to SI201930505T priority patent/SI3759088T1/en
Priority to MX2020008816A priority patent/MX2020008816A/en
Priority to PCT/GB2019/050523 priority patent/WO2019162702A1/en
Priority to BR112020017341-0A priority patent/BR112020017341A2/en
Priority to SG11202007136VA priority patent/SG11202007136VA/en
Priority to RU2020126542A priority patent/RU2816837C2/en
Priority to HUE19710473A priority patent/HUE061751T2/en
Priority to PT197104730T priority patent/PT3759088T/en
Priority to PL19710473.0T priority patent/PL3759088T3/en
Priority to KR1020207025764A priority patent/KR20200126988A/en
Priority to JP2020544648A priority patent/JP7350759B2/en
Priority to LTEPPCT/GB2019/050523T priority patent/LT3759088T/en
Priority to MA052415A priority patent/MA52415A/en
Priority to IL276624A priority patent/IL276624B2/en
Priority to ES19710473T priority patent/ES2941529T3/en
Priority to CA3090864A priority patent/CA3090864A1/en
Priority to US16/975,437 priority patent/US11352332B2/en
Priority to HRP20230290TT priority patent/HRP20230290T1/en
Priority to AU2019223333A priority patent/AU2019223333A1/en
Priority to ZA2020/04220A priority patent/ZA202004220B/en
Priority to CL2020002157A priority patent/CL2020002157A1/en
Priority to US17/830,724 priority patent/US20220306589A1/en
Ceased legal-status Critical Current

Links

GBGB1810667.4A 2018-02-26 2018-06-28 New compounds and uses Ceased GB201810667D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB1810667.4A GB201810667D0 (en) 2018-06-28 2018-06-28 New compounds and uses
AU2019223333A AU2019223333A1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
PT197104730T PT3759088T (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
KR1020207025764A KR20200126988A (en) 2018-02-26 2019-02-26 Triazine derivatives to treat neurotrophin-related diseases
DK19710473.0T DK3759088T3 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
FIEP19710473.0T FI3759088T3 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
SI201930505T SI3759088T1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
MX2020008816A MX2020008816A (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins.
PCT/GB2019/050523 WO2019162702A1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
BR112020017341-0A BR112020017341A2 (en) 2018-02-26 2019-02-26 TRIAZINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROFINS
SG11202007136VA SG11202007136VA (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
RU2020126542A RU2816837C2 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases associated with neurotrophins
HUE19710473A HUE061751T2 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
EP19710473.0A EP3759088B8 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
PL19710473.0T PL3759088T3 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
CN201980014798.6A CN111819172B (en) 2018-02-26 2019-02-26 Triazine derivatives for the treatment of neurotrophin related diseases
JP2020544648A JP7350759B2 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating neurotrophin-related diseases
LTEPPCT/GB2019/050523T LT3759088T (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
MA052415A MA52415A (en) 2018-02-26 2019-02-26 TRIAZINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NEUROTROPHINS
IL276624A IL276624B2 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
ES19710473T ES2941529T3 (en) 2018-02-26 2019-02-26 Triazine derivatives for the treatment of neurotrophin-related diseases
CA3090864A CA3090864A1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
US16/975,437 US11352332B2 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
HRP20230290TT HRP20230290T1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins
ZA2020/04220A ZA202004220B (en) 2018-02-26 2020-07-09 Triazine derivatives for treating diseases relating to neurotrophins
CL2020002157A CL2020002157A1 (en) 2018-02-26 2020-08-21 Triazine derivatives for the treatment of neurotrophin-related diseases.
US17/830,724 US20220306589A1 (en) 2018-02-26 2022-06-02 Triazine derivatives for treating diseases relating to neurotrophins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1810667.4A GB201810667D0 (en) 2018-06-28 2018-06-28 New compounds and uses

Publications (1)

Publication Number Publication Date
GB201810667D0 true GB201810667D0 (en) 2018-08-15

Family

ID=63143726

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1810667.4A Ceased GB201810667D0 (en) 2018-02-26 2018-06-28 New compounds and uses

Country Status (1)

Country Link
GB (1) GB201810667D0 (en)

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
GB201803568D0 (en) Novel compounds and uses
GB201714745D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
IL285177A (en) Compounds and uses thereof
GB201714734D0 (en) New compounds and uses
IL292488B1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
IL277502A (en) Compounds and uses thereof
IL286497A (en) Compounds and uses thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
IL291499A (en) Aza-quinoline compounds and uses thereof
IL284764A (en) Compounds and uses thereof
IL280644A (en) Magnesium-serinate compound and use thereof
GB201714736D0 (en) New compounds and uses
IL285118A (en) Compounds and uses thereof
GB201812078D0 (en) Novel compounds and their uses
IL277749A (en) Pladienolide compounds and their use
GB201801102D0 (en) New compounds and uses
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
IL280369A (en) New myokines and uses thereof
GB201806349D0 (en) New compounds and uses
GB201810667D0 (en) New compounds and uses
ZA202201239B (en) Aminothiolester compounds and uses thereof

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: ALZECURE PHARMA AB

Free format text: FORMER OWNER: STIFTELSEN ALZECURE

AT Applications terminated before publication under section 16(1)